Navigation Links
New nanoparticles target cardiovascular disease
Date:1/18/2010

CAMBRIDGE, Mass. Researchers at MIT and Harvard Medical School have built targeted nanoparticles that can cling to artery walls and slowly release medicine, an advance that potentially provides an alternative to drug-releasing stents in some patients with cardiovascular disease.

The particles, dubbed "nanoburrs" because they are coated with tiny protein fragments that allow them to stick to target proteins, can be designed to release their drug payload over several days. They are one of the first such particles that can precisely home in on damaged vascular tissue, says Omid Farokhzad, associate professor at Harvard Medical School and an author of a paper describing the nanoparticles in the Jan. 18 issue of the Proceedings of the National Academy of Sciences.

Farokhzad and MIT Institute Professor Robert Langer, also an author of the paper, have previously developed nanoparticles that seek out and destroy tumors.

The nanoburrs are targeted to a specific structure, known as the basement membrane, which lines the arterial walls and is only exposed when those walls are damaged. Therefore, the nanoburrs could be used to deliver drugs to treat atherosclerosis and other inflammatory cardiovascular diseases. In the current study, the team used paclitaxel, a drug that inhibits cell division and helps prevent the growth of scar tissue that can clog arteries.

"This is a very exciting example of nanotechnology and cell targeting in action that I hope will have broad ramifications," says Langer.

The researchers hope the particles could become a complementary approach that can be used with vascular stents, which are the standard of care for most cases of clogged and damaged arteries, or in lieu of stents in areas not well suited to them, such as near a fork in the artery.

The particles, which are spheres 60 nanometers in diameter, consist of three layers: an inner core containing a complex of the drug and a polymer chain called PLA; a middle layer of soybean lecithin, a fatty material; and an outer coating of a polymer called PEG, which protects the particle as it travels through the bloodstream.

The drug can only be released when it detaches from the PLA polymer chain, which occurs gradually by a reaction called ester hydrolysis. The longer the polymer chain, the longer this process takes, so the researchers can control the timing of the drug's release by altering the chain length. So far, they have achieved drug release over 12 days, in tests in cultured cells.

In tests in rats, the researchers showed that the nanoburrs can be injected intravenously into the tail and still reach their intended target damaged walls of the left carotid artery. The burrs bound to the damaged walls at twice the rate of nontargeted nanoparticles.

Because the particles can deliver drugs over a longer period of time, and can be injected intravenously, patients would not have to endure repeated and surgically invasive injections directly into the area that requires treatment, says Juliana Chan, a graduate student in Langer's lab and lead author of the paper.

How they did it: The researchers screened a library of short peptide sequences to find one that binds most effectively to molecules on the surface of the basement membrane. They used the most effective one, a seven-amino-acid sequence dubbed C11, to coat the outer layer of their nanoparticles.

Next steps: The team is testing the nanoburrs in rats over a two-week period to determine the most effective dose for treating damaged vascular tissue. The particles may also prove useful in delivering drugs to tumors.

"This technology could have broad applications across other important diseases, including cancer and inflammatory diseases where vascular permeability or vascular damage is commonly observed," says Farokhzad.


'/>"/>

Contact: Jen Hirsch
jfhirsch@mit.edu
617-253-1682
Massachusetts Institute of Technology
Source:Eurekalert

Related biology news :

1. First metallic nanoparticles resistant to extreme heat
2. Small nanoparticles bring big improvement to medical imaging
3. Nanoparticles used in common household items caused genetic damage in mice
4. Behavior modification could ease concerns about nanoparticles
5. Knocking nanoparticles off the socks
6. Clemson bioengineer uses nanoparticles to target drugs
7. Therapeutic nanoparticles give new meaning to sugar-coating medicine
8. Carbon nanoparticles toxic to adult fruit flies but benign to young
9. New insights into health and environmental effects of carbon nanoparticles
10. Facile synthesis of nanoparticles with multiple functions advanced in Singapore
11. University of Leicester researchers discover new fluorescent silicon nanoparticles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/6/2017)... -- Delta ID Inc., a leader in consumer-grade iris scanning ... CES® 2017. Delta ID has collaborated with Gentex Corporation ... of iris scanning as a secure, reliable and convenient ... car, and as a way to elevate the security ... ID and Gentex will demonstrate (booth #7326 LVCC) a ...
(Date:12/22/2016)... YORK , December 22, 2016 ... provider of secure solutions for the e-Government, Public Safety, HealthCare, and ... subsidiary of SuperCom, has been selected to implement and deploy a ... in Northern California , further expanding its presence ... ...
(Date:12/16/2016)... 16, 2016 Research and Markets has announced ... Global Forecast to 2021" report to their offering. ... The biometric vehicle access ... a CAGR of 14.06% from 2016 to 2021. The market is ... to reach 854.8 Million by 2021. The growth of the biometric ...
Breaking Biology News(10 mins):
(Date:1/17/2017)... -- Research and Markets has announced the addition ... Markets and Companies" to their offering. ... The number of ... past few years. More than 1,000 companies have been identified ... these are profiled in the report along with tabulation of ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... Safety Technology Consortium™ (SafeTEC™), $3 million in investment towards 15+ TEC Validation Projects™. ... and assays, and their applicability in drug safety assessment, for the industry as ...
(Date:1/16/2017)... ... January 16, 2017 , ... Appellate Court ... decision on the appeal filed by India-based Dishman Pharmaceutical & Chemical Ltd. company ... DPCL and one of its Dishman Group’s 100% wholly owned New Jersey-based subsidiary ...
(Date:1/14/2017)... Va. , Jan. 13, 2017  The Alliance ... statement in response to FDA final guidance ... for its continued leadership in emphasizing the importance of ... are keenly aware of the benefits biosimilars will bring ...   Yet the portion of the Guidance ...
Breaking Biology Technology: